[WAO Guideline for the Management of Hereditary Angioedema]

Arerugi. 2015 Sep;64(9):1215-41. doi: 10.15036/arerugi.64.1215.
[Article in Japanese]
No abstract available

MeSH terms

  • Allergy and Immunology / organization & administration*
  • Angioedemas, Hereditary / classification
  • Angioedemas, Hereditary / diagnosis*
  • Angioedemas, Hereditary / prevention & control
  • Angioedemas, Hereditary / therapy*
  • Bradykinin B2 Receptor Antagonists / administration & dosage
  • Bradykinin B2 Receptor Antagonists / pharmacology
  • Child
  • Child, Preschool
  • Complement C1 Inhibitor Protein / administration & dosage
  • Danazol / administration & dosage
  • Danazol / adverse effects
  • Diagnosis, Differential
  • Evidence-Based Medicine
  • Female
  • Humans
  • International Cooperation*
  • Kallikreins / antagonists & inhibitors
  • Male
  • Patient Care Planning
  • Peptides / administration & dosage
  • Peptides / pharmacology
  • Practice Guidelines as Topic*
  • Pregnancy
  • Recombinant Proteins
  • Social Support

Substances

  • Bradykinin B2 Receptor Antagonists
  • Complement C1 Inhibitor Protein
  • Peptides
  • Recombinant Proteins
  • ecallantide
  • Kallikreins
  • Danazol